Company Market Research Report: Domain Therapeutics

Company Overview

• Name: Domain Therapeutics

• Mission: Domain Therapeutics is committed to developing innovative therapeutics that unlock the power of the immune system to combat cancer, aimed at transforming and saving lives.

• Founded: No information is available.

• Founders: No information is available.

• Key People:

• Sean A. MacDonald, Chief Executive Officer

• Stephan Schann, Chief Scientific Officer

• Stanislas-Léonard Malmezat, Chief Financial Officer

• Rosemary Mazanet, Senior Medical Advisor

• Nathalie Lenne, Vice-President Strategic Portfolio Management

• Marjorie Sidhoum, Vice-President Business Development & Corporate Communication

• Aurélie Maisner, Director of Human Resources

• Laurence Rulleau, Chairwoman of the Board of Directors

• Prof. Michel Bouvier, Chairman of the Scientific Advisory Board

• Headquarters: Strasbourg - Illkirch, France and Montreal, Canada

• Number of Employees: No information is available.

• Revenue: No information is available.

• Known For: Domain Therapeutics is renowned for pioneering GPCR-targeting cancer immunotherapies and for developing novel therapeutic solutions for non-responding cancer patients.

Products

• DT-9081 (EP4 receptor antagonist)

• Description: An orally administered small molecule designed to block the EP4 receptor on immune cells.

• Key Features: Reverses prostaglandin E2-mediated immunosuppression, demonstrating significant anti-tumor effects in synergy with immune checkpoint inhibitors.

• M1069 (A2aR/A2bR antagonist)

• Description: An antagonist identified in partnership with Merck KGaA targeting A2aR and A2bR receptors.

• Key Features: Designed to enhance antitumor immunity by targeting specific GPCR pathways.

• DT-7012 (Anti-CCR8 depleting antibody)

• Description: A monoclonal antibody designed to deplete tumor-infiltrating regulatory T cells.

• Key Features: Demonstrates unique anti-tumor potency, positioned as a best-in-class candidate in its stage.

• DT-9045 (PAR2 antagonist)

• Description: A PAR2 negative allosteric modulator.

• Key Features: Focused on modulating tumor biology through GPCR pathways.

• Undisclosed GPCR targets

• Description: GPCR targets under discovery phase aimed at bringing new therapeutic solutions to various diseases.

Recent Developments

• Patent and Intellectual Property:

• July 18, 2023: The European Patent Office granted a patent for the EP4 receptor antagonist program, covering candidate DT-9081 until October 2040.

• June 5, 2024: Publication of three international PCT patents enhancing protection for the CCR8 antibody series, including DT-7012.

• Leadership Appointments:

• April 17, 2024: Appointment of Sean A. MacDonald as Chief Executive Officer.

• February 27, 2024: Promotion of Stephan Schann to Chief Scientific Officer.

• Manufacturing and Partnerships:

• March 12, 2024: Domain Therapeutics and Chime Biologics entered into a manufacturing agreement for the candidate DT-7012, focusing on a strategic collaborative approach for production.

• Conferences and Presentations:

• 2 April 2024: Participation in premier investor and healthcare conferences, highlighting the company’s strong focus on partnerships and expansion.

• Clinical Trials:

• April 2023: Ongoing Phase I study (EPRAD) for DT-9081 focusing on advanced, recurrent or metastatic solid tumors to evaluate safety, tolerability, and efficacy.

This report provides an insight into Domain Therapeutics and its strategic focus on GPCR-mediated cancer immunotherapy solutions, bolstered by partnerships and a strong patent strategy.